
Giuseppe Mazzella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1752216/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. Digestive and Liver Disease, 2022, 54, 103-110.	0.9	22
2	A multimedia multilanguage webâ€based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy. Journal of Viral Hepatitis, 2021, 28, 764-770.	2.0	2
3	Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1694.	2.4	20
4	Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 2011.	2.4	16
5	A novel spleenâ€dedicated stiffness measurement by FibroScan® improves the screening of highâ€risk oesophageal varices. Liver International, 2020, 40, 175-185.	3.9	60
6	Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. Ultraschall in Der Medizin, 2020, , .	1.5	15
7	Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Review of Gastroenterology and Hepatology, 2020, 14, 127-135.	3.0	17
8	Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report. Journal of Gastrointestinal and Liver Diseases, 2020, 30, 142-146.	0.9	2
9	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
10	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease, 2019, 51, 681-688.	0.9	49
11	Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 449-456.	0.9	10
12	Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. Digestive and Liver Disease, 2018, 50, 573-579.	0.9	56
13	Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome. Gastroenterology, 2018, 154, 495-497.	1.3	5
14	Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. European Radiology, 2018, 28, 506-513.	4.5	63
15	Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. Gastroenterology Research and Practice, 2018, 2018, 1-11.	1.5	46
16	Imbalance of Neutrophils andÂLymphocyte Counts CanÂBe Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals. Gastroenterology, 2018, 154, 2281-2282.	1.3	7
17	Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. World Journal of Hepatology, 2018, 10, 731-742.	2.0	24
18	Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors. Digestive and Liver Disease, 2017, 49, 1128-1132.	0.9	2

GIUSEPPE MAZZELLA

#	Article	IF	CITATIONS
19	Relationship between indocyanine green retention test, decompensation and survival in patients with Childâ€Pugh A cirrhosis and portal hypertension. Liver International, 2016, 36, 1313-1321.	3.9	29
20	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	27.0	817
21	AISF position paper on liver transplantation and pregnancy. Digestive and Liver Disease, 2016, 48, 860-868.	0.9	20
22	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. Journal of Hepatology, 2016, 65, 727-733.	3.7	768
23	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.9	32
24	The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1481-1484.	1.5	4
25	Reply. Hepatology, 2015, 61, 2113-2114.	7.3	0
26	Extracorporeal shock wave lithotripsy for difficult common bile duct stones: a comparison between 2 different lithotripters in a large cohort of patients. Gastrointestinal Endoscopy, 2015, 81, 402-409.	1.0	17
27	Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature. World Journal of Hepatology, 2015, 7, 1718.	2.0	3
28	Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study. PLoS ONE, 2014, 9, e108112.	2.5	91
29	The future of dual therapy for hepatitis C virus. Future Virology, 2014, 9, 905-912.	1.8	1
30	Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers. Hepatology, 2014, 60, 762-762.	7.3	3
31	Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology, 2014, 59, 643-650.	7.3	91
32	Identification of naÃ ⁻ ve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. Journal of Hepatology, 2014, 60, 16-21.	3.7	25
33	Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: A prospective study. Journal of Hepatology, 2014, 60, 1158-1164.	3.7	123
34	Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma. Journal of Gastroenterology, 2014, 49, 954-955.	5.1	2
35	An unusual cause of weight loss in a young Caucasian man. Gut, 2014, 63, 856.1-856.	12.1	2
36	An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naÃ⁻ve patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 818-825.	0.9	8

#	Article	IF	CITATIONS
37	Berberine and Its Metabolites: Relationship between Physicochemical Properties and Plasma Levels after Administration to Human Subjects. Journal of Natural Products, 2014, 77, 766-772.	3.0	108
38	Telbivudine treatment for fulminant HBV hepatitis. Journal of Digestive Diseases, 2013, 14, n/a-n/a.	1.5	1
39	High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy. PLoS ONE, 2013, 8, e64101.	2.5	12
40	Curcuma longa L. as a Therapeutic Agent in Intestinal Motility Disorders. 2: Safety Profile in Mouse. PLoS ONE, 2013, 8, e80925.	2.5	13
41	Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. World Journal of Gastroenterology, 2013, 19, 5278.	3.3	3
42	Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scandinavian Journal of Gastroenterology, 2012, 47, 1494-1500.	1.5	19
43	Alisporivir for the treatment of chronic HCV. Future Virology, 2012, 7, 9-18.	1.8	1
44	Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients With HCV-Related Cirrhosis. Gastroenterology, 2012, 143, 646-654.	1.3	440
45	Severe acute autoimmune hepatitis after natalizumab treatment. Digestive and Liver Disease, 2012, 44, 356-357.	0.9	31
46	High Dose Lamivudine in HBV-Related Cirrhotic Patients with Unsatisfactory Response After Adefovir Add-On. Digestive Diseases and Sciences, 2012, 57, 561-567.	2.3	2
47	Curcuma longa Extract Exerts a Myorelaxant Effect on the lleum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect. PLoS ONE, 2012, 7, e44650.	2.5	30
48	Ribavirin for chronic hepatitis C: And the mystery goes on. Digestive and Liver Disease, 2011, 43, 425-430.	0.9	22
49	Indocyanine Green Clearance as a Marker of Decompensation and Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis. Gastroenterology, 2011, 140, S-958.	1.3	1
50	Pneumatosis cystoides intestinalis. World Journal of Gastroenterology, 2011, 17, 4932.	3.3	64
51	The Pharmacological Management of Intrahepatic Cholestasis of Pregnancy. Current Clinical Pharmacology, 2011, 6, 12-17.	0.6	70
52	A New Model for Portal Protein Profile Analysis in Course of Ileal Intraluminal Bile Acid Infusion Using an In Situ Perfused Rat Intestine. Medicinal Chemistry, 2011, 7, 257-264.	1.5	8
53	Adverse effects of proton pump inhibitors. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 193-201.	2.4	72
54	ESWL for difficult bile duct stones: A 15-year single centre experience. World Journal of Gastroenterology, 2010, 16, 4159.	3.3	17

GIUSEPPE MAZZELLA

#	Article	IF	CITATIONS
55	The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naÃ⁻ve hepatitis C patients. Hepatology, 2009, 49, 1460-1468.	7.3	208
56	G-CSF in Peg-IFN induced neutropenia in liver transplantedpatients with HCV recurrence. World Journal of Gastroenterology, 2009, 15, 5449.	3.3	12
57	Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis. American Journal of Gastroenterology, 2008, 103, 1966-1972.	0.4	17
58	Lamivudine treatment for severe acute HBV hepatitis. International Journal of Medical Sciences, 2008, 5, 309-312.	2.5	31
59	Proton pump inhibitors in cirrhosis: Tradition or evidence based practice?. World Journal of Gastroenterology, 2008, 14, 2980.	3.3	64
60	Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the) Tj ETQq0	0 0 ₃ .gBT /	Overlock 10
61	Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. , 2008, , 215-236.		0
62	Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases. Current Clinical Pharmacology, 2007, 2, 155-177.	0.6	49
63	Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology, 2007, 45, 579-587.	7.3	585
64	Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy. Digestion, 2006, 73, 94-101.	2.3	45
65	Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World Journal of Gastroenterology, 2006, 12, 4253.	3.3	15
66	Systemic fungemia and hepatic localizations ofFusarium solani in a liver transplanted patient: An emerging fungal agent. Liver Transplantation, 2006, 12, 1711-1714.	2.4	20
67	Is It Possible to Predict the Clinical Course of Gallstone Disease? Usefulness of Gallbladder Motility Evaluation in a Clinical Setting. American Journal of Gastroenterology, 2006, 101, 2576-2581.	0.4	25
68	Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World Journal of Gastroenterology, 2006, 12, 7239.	3.3	74
69	Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis. World Journal of Gastroenterology, 2004, 10, 3099.	3.3	38
70	A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. Journal of Hepatology, 2003, 39, 843-849.	3.7	28
71	Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World Journal of Gastroenterology, 2003, 9, 1487.	3.3	29
72	Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial. World Journal of Gastroenterology, 2003, 9, 1491.	3.3	21

GIUSEPPE MAZZELLA

#	Article	IF	CITATIONS
73	The UDCA dosage deficit: a fate shared with CDCA. European Journal of Gastroenterology and Hepatology, 2002, 14, 213-216.	1.6	5
74	Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study. Journal of Hepatology, 2002, 36, 234.	3.7	3
75	Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Journal of Hepatology, 2001, 34, 570-575.	3.7	677
76	Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers. Hepatology, 2001, 33, 504-508.	7.3	129
77	Efficacy of ursodeoxycholic acid in association with α-interferon for chronic hepatitis C in α-interferon non-responder patients. European Journal of Gastroenterology and Hepatology, 2000, 12, 511-516.	1.6	17
78	Long-Term Results With Interferon Therapy in Chronic Type B Hepatitis: A Prospective Randomized Trial. American Journal of Gastroenterology, 1999, 94, 2246-2250.	0.4	72
79	Sluggish Small Bowel Motility Is Involved in Determining Increased Biliary Deoxycholic Acid in Cholesterol Gallstone Patients. American Journal of Gastroenterology, 1999, 94, 2453-2459.	0.4	25
80	Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. Digestive Diseases and Sciences, 1999, 44, 2478-2483.	2.3	8
81	Clinical manifestations of gallstone disease: Evidence from the multicenter Italian study on cholelithiasis (MICOL). Hepatology, 1999, 30, 839-846.	7.3	84
82	Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Journal of Hepatology, 1996, 24, 141-147.	3.7	300
83	Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Digestive Diseases and Sciences, 1993, 38, 896-902.	2.3	40
84	Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Current Therapeutic Research, 1992, 52, 34-39.	1.2	35
85	Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia. Hepatology, 1992, 15, 1072-1078.	7.3	41
86	Management of intrahepatic cholestasis in pregnancy. Lancet, The, 1991, 338, 1594-1595.	13.7	37
87	Comparative evaluation of chenodeoxycholic and ursodeoxycholic acids in obese patients. Gastroenterology, 1991, 101, 490-496.	1.3	28
88	Gallbladder motility in cholesterol gallstone disease. Gastroenterology, 1990, 99, 1779-1785.	1.3	122
89	A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology, 1989, 10, 336-341.	7.3	96
90	Gallstone recurrence after successful oral bile acid treatment. Gastroenterology, 1989, 97, 726-731.	1.3	190

#	Article	IF	CITATIONS
91	Bile acid malabsorption and bile acid diarrhea in intestinal resection. Digestive Diseases and Sciences, 1982, 27, 495-502.	2.3	82
92	Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: A comparative randomized study. Hepatology, 1982, 2, 804-810.	7.3	136
93	Effect of ursodeoxycholic acid administration on biliary lipid composition and bile acid kinetics in cholesterol gallstone patients. Digestive Diseases and Sciences, 1979, 24, 123-128.	2.3	39